LogicBio Therapeutics, Inc. Proceeds from Common Stock Issued
LogicBio Therapeutics, Inc. reported Proceeds from Common Stock Issued of $45.40 million for the 12-month period ending 2020-12-31, per its 10-K filed 2022-03-04.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2022-03-04
- LogicBio Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2020-12-31 was $42.17M.
- LogicBio Therapeutics, Inc. proceeds from issuance of common stock for the quarter ending 2020-09-30 was $1.32M.
- LogicBio Therapeutics, Inc. proceeds from issuance of common stock for fiscal 2020 was $45.40M.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|
| 2020-12-31 | $42.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-04 | $43.49M derived: sum of 2 quarters · filed 2022-03-04 | $45.40M 10-K · filed 2022-03-04 | |
| 2020-09-30 | $1.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $3.23M 10-Q · filed 2020-11-09 | ||
| 2020-06-30 | $1.91M 10-Q · filed 2020-08-10 |